Dopamine modulates movement, cognitive, and emotional functions of the brain through activation of dopamine receptors that belong to the G protein-coupled receptor (GPCR) superfamily. Here we present the crystal structure of the human dopamine D3 receptor (D3R) in complex with the small molecule D2R/D3R-specific antagonist eticlopride at 3.15 Å resolution. Docking of R-22, a D3R-selective antagonist to the D3R structure reveals an extracellular extension of the eticlopride binding site that comprises a connected second binding pocket for the aryl amide of R-22.Dopamine is an essential neurotransmitter in the central nervous system and exerts its effects through activation of five distinct dopamine receptor subtypes that belong to the G proteincoupled receptor (GPCR) superfamily. The receptors have been classified into two subfamilies, D1-like and D2-like, on the basis of their sequence and pharmacological similarities (1). The D1-like receptors (D1R and D5R) couple to stimulatory G-protein alpha subunits (G s/olf ), activating adenyl cyclase, whereas D2-like receptors (D2R, D3R and D4R) couple to inhibitory G-protein alpha subunits (G i/o ), inhibiting adenyl cyclase. The high degree of sequence identity (2-3) within the transmembrane helices between D2R and D3R

The concept of intrinsic efficacy has been enshrined in pharmacology for half of a century, yet recent data have revealed that many ligands can differentially activate signaling pathways mediated via a single G protein-coupled receptor in a manner that challenges the traditional definition of intrinsic efficacy. Some terms for this phenomenon include functional selectivity, agonist-directed trafficking, and biased agonism. At the extreme, functionally selective ligands may be both agonists and antagonists at different functions mediated by the same receptor. Data illustrating this phenomenon are presented from serotonin, opioid, dopamine, vasopressin, and adrenergic receptor systems. A variety of mechanisms may influence this apparently ubiquitous phenomenon. It may be initiated by differences in ligand-induced intermediate conformational states, as shown for the ␤ 2 -adrenergic receptor. Subsequent mechanisms that may play a role include diversity of G proteins, scaffolding and signaling partners, and receptor oligomers. Clearly, expanded research is needed to elucidate the proximal (e.g., how functionally selective ligands cause conformational changes that initiate differential signaling), intermediate (mechanisms that translate conformation changes into differential signaling), and distal mechanisms (differential effects on target tissue or organism). Besides the heuristically interesting nature of functional selectivity, there is a clear impact on drug discovery, because this mechanism raises the possibility of selecting or designing novel ligands that differentially activate only a subset of functions of a single receptor, thereby optimizing therapeutic action. It also may be timely to revise classic concepts in quantitative pharmacology and relevant pharmacological conventions to incorporate these new concepts. Receptor Pharmacology for the New MillenniumFor the last half-century, pharmacological theory has posited that ligands could be characterized by the nature of the functional effects elicited by their interaction with their tar-

Eukaryotic neurotransmitter:sodium symporters (NSSs), targets for antidepressants and psychostimulants, terminate neurotransmission by sodium-driven reuptake. The crystal structure of LeuT(Aa), a prokaryotic NSS homolog, revealed an occluded state in which one leucine and two Na(+) ions are bound, but provided limited clues to the molecular mechanism of transport. Using steered molecular dynamics simulations, we explored the substrate translocation pathway of LeuT. We identified a second substrate binding site located in the extracellular vestibule comprised of residues shown recently to participate in binding tricyclic antidepressants. Binding and flux experiments showed that the two binding sites can be occupied simultaneously. The substrate in the secondary site allosterically triggers intracellular release of Na(+) and substrate from the primary site, thereby functioning as a "symport effector." Because tricyclic antidepressants bind differently to this secondary site, they do not promote substrate release from the primary site and thus act as symport uncouplers and inhibit transport.

The movements of transmembrane segments (TMs) 3 and 6 at the cytoplasmic side of the membrane play an important role in the activation of G-protein-coupled receptors. Here we provide evidence for the existence of an ionic lock that constrains the relative mobility of the cytoplasmic ends of TM3 and TM6 in the inactive state of the ␤ 2 -adrenergic receptor. We propose that the highly conserved Arg-131 3.50 at the cytoplasmic end of TM3 interacts both with the adjacent Asp-130 3.49 and with Glu-268 6.30 at the cytoplasmic end of TM6. Such a network of ionic interactions has now been directly supported by the high-resolution structure of the inactive state of rhodopsin. We hypothesized that the network of interactions would serve to constrain the receptor in the inactive state, and the release of this ionic lock could be a key step in receptor activation. To test this hypothesis, we made charge-neutralizing mutations of Glu-268 The majority of hormones and neurotransmitters exerts its cellular effects by activating cell surface receptors belonging to the superfamily of G-protein-coupled receptors (GPCRs) 1 (1-3). The ␤ 2 -adrenergic receptor (␤ 2 AR) belongs to the subfamily of rhodopsin-like receptors and has been used as a prototype GPCR in numerous studies (1-3). Low-resolution structures of rhodopsin, resolved by Schertler and co-workers (4, 5), have demonstrated the presence of seven membrane-spanning ␣-helical segments and have provided important insights into the organization of the transmembrane bundle, allowing the development of tertiary structure models of GPCRs (6 -8). Importantly, a high-resolution structure of rhodopsin has now become available (9) making it possible to consider the functional roles of individual side chains from the perspective of an atomic resolution structure of a homologous GPCR.Understanding the function of GPCRs at a molecular level requires an understanding of how agonist binding to the receptor is converted into receptor activation (3). Studies based on EPR spectroscopy, fluorescence spectroscopy, alterations in cysteine accessibility, and engineering of metal-binding sites have altogether pointed to a key role for conformational changes of . The molecular mechanisms that underlie the movements of TM3 and TM6 and govern the transition of the receptor between its inactive and active states have nonetheless remained unclear. It has been suggested that the protonation of the aspartic acid in the highly conserved (D/E)RY motif at the cytoplasmic side of TM3 leads to a release of constraining intramolecular interactions, thereby resulting in the movements of TM3 and TM6 and a conversion of the receptor to the active state (7,14,16). This hypothesis has been supported by the observation that charge-neutralizing mutations of the aspartic acid (or glutamic acid) in TM3 lead to increased agonist-independent activation of a number of GPCRs (7,14,17,18). Moreover, direct evidence has been obtained indicating that the photoactivation of rhodopsin is accompanied by the uptake of a proton b...

N-Methyl -4 -phenyl -1,2,3,6 -tetrahydropyridine (MPTP) produces neuropathological and clinical abnormalities in humans, monkeys, and mice that closely resemble idiopathic parkinsonism. N-Methyl-4-phenylpyridine (MPP+), a metabolite of MPTP formed by monoamine oxidase B, is accumulated into striatal and cerebral cortical synaptosomes by the dopamine and norepinephrine uptake systems, respectively, whereas MPTP itself is not accumulated. N-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) is a by-product of the chemical synthesis of an analog of the opiate meperidine. In humans MPTP produces apparently irreversible symptoms clinically similar to those found in parkinsonism (1)(2)(3)(4). After MPTP administration to humans, monkeys, and mice, pathological lesions and neurochemical changes are prominent in nigrostriatal dopaminergic neurons (1-11), although other catecholaminergic neurons are also affected (5,7,10).MPTP neurotoxicity is dependent on its conversion by monoamine oxidase B (MAO B) to N-methyl-4-phenylpyridine (MPP+) (12, 13). Deprenyl or pargyline, selective MAO B inhibitors, block the conversion of MPTP to MPP+ in brain mitochondrial preparations (14). Pretreatment of mice (15) and monkeys (16) with MAO inhibitors prevents the neurotoxic action of MPTP.[3H]MPTP binds with high affinity to receptor-like sites that reflect the initial recognition sites for the neurotoxic process (17). Thus, the chemical specificity of the binding sites parallels the ability to elicit neurotoxicity (17). Also, [3H]MPTP binding sites are concentrated in human substantia nigra and caudate, whereas these regions have substantially fewer binding sites in rats (17), in accordance with the lesser neurotoxicity of MPTP in this species (18)(19)(20)(21)(22) For uptake experiments, corpus striatum or cerebral cortex from male Sprague-Dawley rats (150-250 g, Charles River Breeding Laboratories) was homogenized in ice-cold 0.3 M sucrose in a glass homogenizer with a Teflon pestle, using 20 or 5 vol for corpus striatum or cerebral cortex, respectively. The homogenate was centrifuged at 1000 x g for 10 min. The supernatant was centrifuged at 12,000 x g for 20 min. and various tested drugs. After incubation at 37°C for 6 min the uptake was terminated by the addition of 4 ml of ice-cold buffer to each tube and filtration of the mixture through glass-fiber filters (Schleicher & Schuell no. 32). Filters were washed with two consecutive 2-ml aliquots of buffer. Radioactivity remaining on the filters was measured by liquid Abbreviations: MPTP, N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine; MPP+, N-methyl-4-phenylpyridine; MAO, monoamine oxidase. §To whom reprint requests should be addressed. 2173The publication costs of this article were defrayed in part by page charge payment. This article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. §1734 solely to indicate this fact.

Cocaine is a widely abused substance with psychostimulant effects that are attributed to inhibition of the dopamine transporter (DAT). We present molecular models for DAT binding of cocaine and cocaine analogs constructed from the high-resolution structure of the bacterial transporter homolog LeuT. Our models suggest that the binding site for cocaine and cocaine analogs is deeply buried between transmembrane segments 1, 3, 6 and 8, and overlaps with the binding sites for the substrates dopamine and amphetamine, as well as for benztropine-like DAT inhibitors. We validated our models by detailed mutagenesis and by trapping the radiolabeled cocaine analog [ 3 H]CFT in the transporter, either by cross-linking engineered cysteines or with an engineered Zn 2+ -binding site that was situated extracellularly to the predicted common binding pocket. Our data demonstrate the molecular basis for the competitive inhibition of dopamine transport by cocaine.Correspondence should be addressed to U.G. (E-mail: gether@sund.ku.dk). Note: Supplementary information is available on the Nature Neuroscience website. AUTHOR CONTRIBUTIONST.B. designed and performed the computational experiments, analyzed the data and wrote the manuscript draft together with C.J.L. J.K. generated mutants, carried out pharmacological analyses and contributed to the data analysis. M.L.B. and K.R. generated mutants and carried out pharmacological analyses. L.S. contributed to the computational experiments and manuscript refinement. L.G. participated in the design and performance of the computational experiments. A.H.N. contributed with ideas, benztropine analogues and provided expertise in the pharmacology and medicinal chemistry of DAT inhibitors. J.A.J. contributed with ideas and to the design of experiments and writing of the manuscript. H.W. directed the design and performance of the modeling and computational experiments, participated in data analysis and contributed to writing the manuscript. U.G. supervised the project together with C.J.L., designed experiments, analyzed data and wrote the final manuscript. C.J.L. supervised the project together with U.G., designed experiments, generated mutants, performed pharmacological experiments, analyzed data and wrote the manuscript draft together with T.B.Reprints and permissions information is available online at http://npg.nature.com/reprintsandpermissions/ NIH Public Access Author ManuscriptNat Neurosci. Author manuscript; available in PMC 2009 July 1. Published in final edited form as:Nat Neurosci. 2008 July ; 11(7): 780-789. doi:10.1038/nn.2146. NIH-PA Author ManuscriptNIH-PA Author Manuscript NIH-PA Author ManuscriptCocaine is an alkaloid derived from the Peruvian Erythroxylon coca plant and has been used as a stimulant for centuries 1 . Today, cocaine is widely abused, especially in the western hemisphere, causing major socioeconomic burdens through increased medical expenses, lost earnings and increased crime 2 . Nonetheless, the molecular mechanisms underlying cocaine's pharmacology and abuse ...

Elucidating the key signal transduction pathways essential for both antipsychotic efficacy and side-effect profiles is essential for developing safer and more effective therapies. Recent work has highlighted noncanonical modes of dopamine D 2 receptor (D 2 R) signaling via β-arrestins as being important for the therapeutic actions of both antipsychotic and antimanic agents. We thus sought to create unique D 2 R agonists that display signaling bias via β-arrestinergic signaling. Through a robust diversity-oriented modification of the scaffold represented by aripiprazole (1), we discovered UNC9975 (2), UNC0006 (3), and UNC9994 (4) as unprecedented β-arrestin-biased D 2 R ligands. These compounds also represent unprecedented β-arrestin-biased ligands for a G i -coupled G proteincoupled receptor (GPCR). Significantly, UNC9975, UNC0006, and UNC9994 are simultaneously antagonists of G i -regulated cAMP production and partial agonists for D 2 R/β-arrestin-2 interactions. Importantly, UNC9975 displayed potent antipsychotic-like activity without inducing motoric side effects in inbred C57BL/6 mice in vivo. Genetic deletion of β-arrestin-2 simultaneously attenuated the antipsychotic actions of UNC9975 and transformed it into a typical antipsychotic drug with a high propensity to induce catalepsy. Similarly, the antipsychotic-like activity displayed by UNC9994, an extremely β-arrestin-biased D 2 R agonist, in wild-type mice was completely abolished in β-arrestin-2 knockout mice. Taken together, our results suggest that β-arrestin signaling and recruitment can be simultaneously a significant contributor to antipsychotic efficacy and protective against motoric side effects. These functionally selective, β-arrestin-biased D 2 R ligands represent valuable chemical probes for further investigations of D 2 R signaling in health and disease.functional selectivity | ligand bias G protein-coupled receptors (GPCRs) signal not only via canonical pathways involving heterotrimeric large G proteins, but also via noncanonical G protein-independent interactions with other signaling proteins including, most prominently, β-arrestins (1-4). The process by which GPCR ligands differentially modulate canonical and noncanonical signal transduction pathways is a phenomenon known as "functional selectivity" (5, 6). Such functionally selective ligands preferentially engage either canonical or noncanonical GPCR pathways (7,8). Clearly, the discovery of ligands with discrete functional selectivity profiles will be extremely useful for elucidating the key signal transduction pathways essential for both the therapeutic actions and the side effects of drugs (6). Understanding which signaling pathways contribute to antipsychotic efficacy and side effects, for instance, will in turn enable the design of better antipsychotic drug candidates and, ultimately, lead to safer and more effective therapies for patients. However, only a small number of functionally selective GPCR ligands have been reported to date (5-9). In addition to the paucity of such ligands,...

The dopamine transporter (DAT) is a target of amphetamine (AMPH) and cocaine. These psychostimulants attenuate DAT clearance efficiency, thereby increasing synaptic dopamine (DA) levels. Re-uptake rate is determined by the number of functional transporters at the cell surface as well as by their turnover rate. Here, we present evidence that DAT substrates, including AMPH and DA, cause internalization of human DAT, thereby reducing transport capacity. Acute treatment with AMPH reduced the maximal rate of Dopamine (DA) signaling in the central nervous system mediates a wide variety of physiologic functions such as movement, motivational control of voluntary behavior, and lactation (1, 2). The magnitude and duration of DA signaling is defined by the amount of vesicular release, the sensitivity of the DA receptors, and the efficiency of DA clearance. The DA transporter (DAT) is largely responsible for regulating DA clearance (3).Psychostimulants, such as cocaine and amphetamine (AMPH), induce DA overflow into the synaptic cleft by acting on the DAT, thereby enhancing dopaminergic transmission (4). Cocaine acts by inhibiting the re-uptake of released DA (5, 6). AMPH-like drugs, however, are thought to promote the release of the transmitter (carrier-mediated efflux) as well as to inhibit its uptake (7,8). Repeated administration of AMPH has been shown to sensitize monoaminergic synapses to subsequent psychostimulant challenge (9). Furthermore, administration of a single, high dose of AMPH acutely (1 h) decreased DAT function in vivo as assessed in striatal synaptosomes prepared from drug-treated rats (10). In contrast, administration of a high dose of cocaine had no effect on subsequent transporter activity (10).To explore the mechanism for the differential effects of AMPH and cocaine on the homeostatic uptake capacity of the human DAT (hDAT), we stably expressed a FLAG-tagged hDAT in EM4 cells (see Materials and Methods). The use of the FLAG fusion protein has provided the opportunity for confocal microscopy analysis of trafficking of the transporter in cells. Here, we report that AMPH caused the hDAT to redistribute intracellularly in a dynamindependent manner, consequently reducing subsequent DA transport capacity. These results provide a mechanism for the AMPHinduced elevation of synaptic DA mediated through a reduction of the number of transporters on the cell surface. Materials and MethodsCell Culture. We created a synthetic hDAT gene, which was tagged at the amino terminus with a FLAG epitope. The gene encodes a protein with an amino acid sequence identical to that of wild-type hDAT with the Met at position 1 replaced by MDYKDDDDKA, but the nucleotide sequence was altered to increase the number of unique restriction sites and to optimize codon utilization. The nucleotide sequence of this construct and its creation will be described elsewhere. The FLAG-tagged syntheticDAT was subcloned into a bicistronic expression vector that expresses the syntheticDAT from a cytomegalovirus promoter and the hygromycin resista...